Last reviewed · How we verify

Capecitabine and Sorafenib

SCRI Development Innovations, LLC · Phase 1 active Small molecule

Capecitabine and Sorafenib is a Small molecule drug developed by SCRI Development Innovations, LLC. It is currently in Phase 1 development. Also known as: Xeloda, Nexavar.

At a glance

Generic nameCapecitabine and Sorafenib
Also known asXeloda, Nexavar
SponsorSCRI Development Innovations, LLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Capecitabine and Sorafenib

What is Capecitabine and Sorafenib?

Capecitabine and Sorafenib is a Small molecule drug developed by SCRI Development Innovations, LLC.

Who makes Capecitabine and Sorafenib?

Capecitabine and Sorafenib is developed by SCRI Development Innovations, LLC (see full SCRI Development Innovations, LLC pipeline at /company/scri-development-innovations-llc).

Is Capecitabine and Sorafenib also known as anything else?

Capecitabine and Sorafenib is also known as Xeloda, Nexavar.

What development phase is Capecitabine and Sorafenib in?

Capecitabine and Sorafenib is in Phase 1.

Related